Alpa LaboratoriesNSE:ALPA -0.70%73 Interest Coverage is 22.71 as of Mar. 2026, which is 6% below its 10-year median of 24.16. GuruFocus rates NSE:ALPA with a GF Score™ of 73/100 and a GF Value™ of ₹91.65 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 684 Drug Manufacturers companies, Alpa Laboratories ranks worse than 71.93% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Alpa Laboratories's
Operating Income
for the
three
months ended in Mar. 2026 was ₹34 Mil. Alpa Laboratories's Interest Expense for the
three
months ended in Mar. 2026 was ₹-1 Mil.
Alpa Laboratories's interest coverage for the quarter that ended in Mar. 2026 was 22.71.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Alpa Laboratories's Interest Coverage or its related term are showing as below:
NSE:ALPA'
s Interest Coverage Range Over the Past 10 Years
Min: 2.72 Med: 24.16 Max: 372.28
Current: 4.65
NSE:ALPA's Interest Coverage is ranked worse than 71.93% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs NSE:ALPA: 4.65
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Alpa Laboratories Interest Coverage Related Terms
Alpa Laboratories Interest Coverage Historical Data
* Premium members only.
The historical data trend for Alpa Laboratories's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:ALPA vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alpa Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpa Laboratories Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alpa Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Alpa Laboratories's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpa Laboratories (NSE:ALPA) has a Interest Coverage of 22.71 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Alpa Laboratories and its competitors. This is near median its historical median of 24.16. Over the past decade, Alpa Laboratories' Interest Coverage has ranged from 2.72 to 372.28. According to the industry distribution chart, Alpa Laboratories ranks #492 out of 684 companies in the Drug Manufacturers industry, placing it in the top 71.9%.
Is Alpa Laboratories' Interest Coverage too high?
Alpa Laboratories' current Interest Coverage of 22.71 is near median its 10-year median of 24.16. Over the past 10 years, this metric has ranged from a low of 2.72 to a high of 372.28. The Drug Manufacturers industry median Interest Coverage is 12.77. Alpa Laboratories' value of 22.71 is 77.9% above this industry median. Based on the distribution chart, Alpa Laboratories ranks #492 out of 684 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alpa Laboratories has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alpa Laboratories' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alpa Laboratories ranks #492 out of 684 companies for Interest Coverage. This places Alpa Laboratories in the lower half of its industry. The industry median Interest Coverage is 12.77. Alpa Laboratories' value of 22.71 is 77.9% above this benchmark. Historically, Alpa Laboratories' own Interest Coverage has ranged from 2.72 to 372.28 over the past decade. While the company's 10-year median is 24.16 vs. the industry median of 12.77, Alpa Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpa Laboratories's current Interest Coverage of 22.71 is 77.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Alpa Laboratories and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpa Laboratories's current Interest Coverage is 22.71, which is near median its own 10-year median of 24.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alpa Laboratories (NSE:ALPA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹91.65, compared to a current price of ₹68.02 — trading 25.8% below its estimated fair value. The current Interest Coverage is 22.71, which is near median its 10-year median of 24.16 and 77.9% above the Drug Manufacturers industry median of 12.77. Alpa Laboratories' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Alpa Laboratories (NSE:ALPA), the current Interest Coverage is 22.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpa Laboratories (NSE:ALPA) Overvalued in 2026?
Based on GuruFocus' analysis, Alpa Laboratories stock appears to be undervalued.
The current stock price of ₹68.02 is trading 25.8% below its estimated GF Value™ of ₹91.65.
GuruFocus considers Alpa Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:ALPA:
Interest Coverage: 22.71 (near median its 10-year median of 24.16)
GF Value™: ₹91.65 vs. price of ₹68.02 (25.8% below fair value)
Industry Position: 77.9% above the Drug Manufacturers median (#492 of 684)
No single metric tells the full story. See the NSE:ALPA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpa Laboratories Ltd is an India-based pharmaceutical company. It operates in the drug and chemical business segment. The company manufactures and markets pharmaceuticals and related products. It sells products like liquid injection, dry powder injection, tablets, capsules, and ointments.
73GF Score
Get the complete analysis for NSE:ALPA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALPA has been successfully added to your 
